Replies to post #117700 on Biotech Values

[ThomasS]

What is an example of a "price-sensitive" country, that presumably places cost above cure?
Wouldn't the practice cost more in the long run to not include the PI?
The current treatment already costs plenty, yet, doesn't work well.
IMO, ridiculous opinion from whatever source...

[DewDiligence]

Re: Using IL28B status to dictate treatment

I read an opinion (cannot find the link but think it was someone like Jules Levin, who attended EASL), that in price sensitive countries, naïve CC genotype patients will get peg-INF+Riba and the PI will be added only if patients don't achieve RVR.

I could see doing that if clinicians had a very strong biomarker for treatment success on SoC; however, IL28B by itself does not fit the bill, IMO. Hence, I’m inclined to agree with ThomasS that giving Telaprevir to only the patients who fail to achieve RVR on SoC is likely to backfire in terms of economics (in addition to being bad medicine).